Literature DB >> 21471241

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.

Mena Mansour1, Peter Palese, Dmitriy Zamarin.   

Abstract

Newcastle disease virus (NDV) is a negative-sense RNA virus that has been shown to possess oncolytic activity. NDV's selective replication in tumor cells has been previously suggested to be due to the lack of a proper antiviral response in these cells. Here we demonstrate that NDV possesses oncolytic activity in tumor cells capable of a robust type I interferon (IFN) response, suggesting that another mechanism underlies NDV's tumor specificity. We show that the oncolytic selectivity of NDV for tumor cells is dependent upon tumor cell resistance to apoptosis. Utilizing the human non-small-cell lung cancer cell line A549 overexpressing the antiapoptotic protein Bcl-xL, we show significant enhancement of oncolytic activity and NDV replication. Interestingly, while the Bcl-xL-overexpressing cells were resistant to apoptotic stimuli induced by chemotherapeutic agents and early viral replication, during the subsequent viral cycles, we observed a paradoxical increase in apoptosis in response to NDV. The increased oncolytic activity seen was secondary to enhanced viral replication and syncytium formation. The induction of a type I IFN response was enhanced in Bcl-xL cells. Overall, these findings propose a new mechanism for cancer cell specificity for NDV, making it an attractive anticancer agent for chemoresistant tumors with enhanced antiapoptotic activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471241      PMCID: PMC3126310          DOI: 10.1128/JVI.01537-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Viruses and apoptosis.

Authors:  A Roulston; R C Marcellus; P E Branton
Journal:  Annu Rev Microbiol       Date:  1999       Impact factor: 15.500

2.  Type I interferon and cancer immunoediting.

Authors:  Mark J Smyth
Journal:  Nat Immunol       Date:  2005-07       Impact factor: 25.606

3.  Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.

Authors:  Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal
Journal:  Mol Ther       Date:  2005-10-28       Impact factor: 11.454

4.  Newcastle disease virus selectively kills human tumor cells.

Authors:  K W Reichard; R M Lorence; C J Cascino; M E Peeples; R J Walter; M B Fernando; H M Reyes; J A Greager
Journal:  J Surg Res       Date:  1992-05       Impact factor: 2.192

5.  Fusion regulation proteins on the cell surface: isolation and characterization of monoclonal antibodies which enhance giant polykaryocyte formation in Newcastle disease virus-infected cell lines of human origin.

Authors:  Y Ito; H Komada; S Kusagawa; M Tsurudome; H Matsumura; M Kawano; H Ohta; M Nishio
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

6.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.

Authors:  B Yaacov; E Eliahoo; E Elihaoo; I Lazar; M Ben-Shlomo; I Greenbaum; A Panet; Z Zakay-Rones
Journal:  Cancer Gene Ther       Date:  2008-06-06       Impact factor: 5.987

8.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.

Authors:  Dmitriy Zamarin; Luis Martínez-Sobrido; Kaitlyn Kelly; Mena Mansour; Gang Sheng; Adam Vigil; Adolfo García-Sastre; Peter Palese; Yuman Fong
Journal:  Mol Ther       Date:  2009-02-10       Impact factor: 11.454

9.  Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.

Authors:  B Washburn; V Schirrmacher
Journal:  Int J Oncol       Date:  2002-07       Impact factor: 5.650

10.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more
  63 in total

1.  Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions.

Authors:  Nicole B Glennon; Omar Jabado; Michael K Lo; Megan L Shaw
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Cell-type-specific innate immune response to oncolytic Newcastle disease virus.

Authors:  Moanaro Biswas; Sandeep R P Kumar; Adria Allen; Wang Yong; Ramadevi Nimmanapalli; Siba K Samal; Subbiah Elankumaran
Journal:  Viral Immunol       Date:  2012-07-18       Impact factor: 2.257

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.

Authors:  P R A Buijs; C H J van Eijck; L J Hofland; R A M Fouchier; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

Review 6.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

7.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

Review 8.  The Role of Oncolytic Viruses in the Treatment of Melanoma.

Authors:  Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Oncol Rep       Date:  2018-08-25       Impact factor: 5.075

Review 9.  The therapeutic effect of death: Newcastle disease virus and its antitumor potential.

Authors:  Sara Cuadrado-Castano; Maria T Sanchez-Aparicio; Adolfo García-Sastre; Enrique Villar
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

10.  Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.

Authors:  Samantha B Kasloff; Matteo S Pizzuto; Micol Silic-Benussi; Silvia Pavone; Vincenzo Ciminale; Ilaria Capua
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.